Skip to main content

Advertisement

SpringerLink
Log in

Long-term treatment of osteoporotic women with bisphosphonates does not impair the response to subsequently administered intravenous pamidronate

  • Short Communication
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Summary

We addressed the question whether the response of osteoporotic patients to bisphosphonate treatment is reduced with time. Bisphosphonate-treated women with postmenopausal or glucocorticoid-induced osteoporosis showed adequate and consistent changes of bone markers to subsequently administered intravenous pamidronate. Response of osteoporotic patients to bisphosphonates is not impaired during their long-term administration.

Introduction

Inadequate response to bisphosphonate treatment has been described in patients with Paget’s disease of bone but has not been addressed in osteoporosis although treatment failure is a clinically relevant problem.

Methods

Twenty one women with postmenopausal osteoporosis (PMO) aged 68 ± 8.2 years and 14 women with glucocorticoid-induced osteoporosis (GIOP) aged 65 ± 10 years were treated with tri-monthly intravenous infusions of 45 mg of pamidronate for 1 year. All patients had been previously treated with bisphosphonates (alendronate, risedronate, pamidronate) for a mean period of 6.2 years (range, 1.3–14 years). Blood samples were taken for measurement of the bone resorption marker C-terminal crosslinking telopeptide of type I collagen (CTX-I) on days 1 and 4 and of the bone formation marker procollagen type I N propeptide, (P1NP) on day 1 of every tri-monthly treatment course.

Results

With each treatment course there was a significant decrease in serum CTX-I on day 4 and an increase to baseline values 3 months after each infusion in both PMO (mean values, day 1: 291.33 ± 160.78 pg/ml vs. day 4: 131 ± 91.7 pg/ml, p < 0.001) and GIOP (day 1: 219.3 ± 114.8 pg/ml vs. day 4: 98.8 ± 51.6 pg/ml, p < 0.001). Serum P1NP remained stable during the whole year of treatment.

Conclusions

Long-term bisphosphonate treatment of women with either PMO or GIOP does not impair the response to subsequently administered intravenous pamidronate suggesting that inadequate response to long-term bisphosphonate treatment is not responsible for treatment failure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Diez-Perez A, Adachi JD, Agnusdei D, Bilezikian JP, Compston JE, Cummings SR, Eastell R, Eriksen EF, Gonzalez-Macias J, Liberman UA, Wahl DA, Seeman E, Kanis JA, Cooper C, The IOF CSA Inadequate Responders Working Group (2012) Treatment failure in osteoporosis. Osteoporos Int 23(12):2769–74. doi:10.1007/s00198-012-2093-8

    Google Scholar 

  2. Adami S, Isaia G, Minisola S, Sinigaglia L, Gentilella R, Agnusdei D, Iori N, Nuti R, ICARO Study Group (2006) Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study. J Bone Miner Res 21:1565–1570

    Article  PubMed  CAS  Google Scholar 

  3. Díez-Pérez A, Olmos JM, Nogués X, Sosa M, Díaz-Curiel M, Pérez-Castrillón JL, Pérez-Cano R, Muñoz-Torres M, Torrijos A, Jodar E, Del Rio L, Caeiro-Rey JR, Farrerons J, Vila J, Arnaud C, González-Macías J (2012) Risk factors for prediction of inadequate response to antiresorptives. J Bone Miner Res 27:817–824

    Article  PubMed  Google Scholar 

  4. Altman RD (1985) Long-term follow-up of therapy with intermittent etidronate disodium in Paget’s disease of bone. Am J Med 79:583–590

    Article  PubMed  CAS  Google Scholar 

  5. Gutteridge DH, Ward LC, Stewart GO, Retallack RW, Will RK, Prince RL, Criddle A, Bhagat CI, Stuckey BG, Price RI, Kent GN, Faulkner DL, Geelhoed E, Gan SK, Vasikaran S (1999) Paget’s disease: acquired resistance to one aminobisphosphonate with retained response to another. J Bone Miner Res 14:79–84

    Article  PubMed  CAS  Google Scholar 

  6. Trombetti A, Arlot M, Thevenon J, Uebelhart B, Meunier PJ (1999) Effect of multiple intravenous pamidronate courses in Paget’s disease of bone. Rev Rhum Engl Ed 66:467–476

    PubMed  CAS  Google Scholar 

  7. Papapoulos SE, Eekhoff EM, Zwinderman AH (2006) Acquired resistance to bisphosphonates in Paget's disease of bone. J Bone Miner Res 21(Suppl 2):P88–91

    Article  PubMed  CAS  Google Scholar 

  8. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA, Alendronate Phase III Osteoporosis Treatment Study Group (2004) Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189–99

    Article  PubMed  CAS  Google Scholar 

  9. Mellström DD, Sörensen OH, Goemaere S, Roux C, Johnson TD, Chines AA (2004) Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 75:462–8

    Article  PubMed  Google Scholar 

  10. Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, Cummings SR, Hue TF, Lippuner K, Lakatos P, Leung PC, Man Z, Martinez RL, Tan M, Ruzycky ME, Su G, Eastell R (2012) The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 27:243–54

    Article  PubMed  CAS  Google Scholar 

  11. Miller PD, Recker RR, Reginster JY, Riis BJ, Czerwinski E, Masanauskaite D, Kenwright A, Lorenc R, Stakkestad JA, Lakatos P (2012) Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study. Osteoporos Int 23:1747–56

    Article  PubMed  CAS  Google Scholar 

  12. Iba K, Takada J, Hatakeyama N, Ozasa Y, Wada T, Yamashita T (2008) Changes in urinary NTX levels in patients with primary osteoporosis undergoing long-term bisphosphonate treatment. J Orthop Sci 13:438–41

    Article  PubMed  CAS  Google Scholar 

  13. van Beek ER, Cohen LH, Leroy IM, Ebetino FH, Löwik CW, Papapoulos SE (2003) Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone 33:805–11

    Article  PubMed  Google Scholar 

  14. Cauza E, Etemad M, Winkler F, Hanusch-Enserer U, Partsch G, Noske H, Dunky A (2004) Pamidronate increases bone mineral density in women with postmenopausal or steroid-induced osteoporosis. J Clin Pharm Ther 29:431–6

    Article  PubMed  CAS  Google Scholar 

  15. Hernández MV, Peris P, Monegal A, Reyes R, Muxi A, Gifre L, Guañabens N (2010) Effects of intravenous pamidronate on renal function, bone mineral metabolism and bone mass in patients with severe osteoporosis. Am J Med Sci 339:225–9

    Article  PubMed  Google Scholar 

  16. Makras P, Hamdy NAT, Zwinderman AH, Ballieux BEPB, Papapoulos SE (2009) Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis. Bone 44:766–71

    Article  PubMed  CAS  Google Scholar 

  17. McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J (2007) Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 41:122–8

    Article  PubMed  CAS  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands

    M. P. Yavropoulou, N. A. T. Hamdy & S. E. Papapoulos

Authors
  1. M. P. Yavropoulou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. A. T. Hamdy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. E. Papapoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. E. Papapoulos.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yavropoulou, M.P., Hamdy, N.A.T. & Papapoulos, S.E. Long-term treatment of osteoporotic women with bisphosphonates does not impair the response to subsequently administered intravenous pamidronate. Osteoporos Int 24, 2353–2357 (2013). https://doi.org/10.1007/s00198-013-2301-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-013-2301-1

Keywords

Search

Navigation